dc.creatorRojas, Armando
dc.creatorMercadal, Enrique
dc.creatorFigueroa, Hector
dc.creatorMorales, Miguel A.
dc.date.accessioned2018-12-20T15:10:01Z
dc.date.available2018-12-20T15:10:01Z
dc.date.created2018-12-20T15:10:01Z
dc.date.issued2008
dc.identifierCurrent Vascular Pharmacology, Volumen 6, Issue 1, 2018, Pages 44-51
dc.identifier15701611
dc.identifier10.2174/157016108783331312
dc.identifierhttps://repositorio.uchile.cl/handle/2250/158109
dc.description.abstractDespite many advances achieved to date, heart failure (HF) remains a leading cause of morbidity and mortality. There is a widely-accepted consensus that HF and diabetes are strongly linked by at least 3 mechanisms: associated comorbidities, coronary atherosclerosis or a specific diabetic cardiomiopathy. For the last 2 mechanisms, advanced glycation end-products may contribute to trigger key processes relevant to HF by affecting cardiac function through cross-linking or receptor engagement. This review focuses on the main effects of advanced glycation end-products on cardiomyocytes and endothelial cell function. Some pharmacological approaches ara also discussed. © 2008 Bentham Science Publishers Ltd.
dc.languageen
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
dc.sourceCurrent Vascular Pharmacology
dc.subjectAdvanced glycation
dc.subjectCardiomyocytes
dc.subjectDiabetes
dc.subjectGlucose imbalance
dc.subjectHeart failure
dc.subjectOxidative stress
dc.titleAdvanced glycation and ROS: A link between diabetes and heart failure
dc.typeArtículo de revista


Este ítem pertenece a la siguiente institución